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Risk factors for local recurrence in breast cancer after breast 
conserving therapy (BCT) differ from those for local recurrence after 
mastectomy. To better guide optimal treatment of individual 
patients, it is desirable to identify patients at high risk for local 
recurrence. Several clinical and histopathological factors, such as 
young age and presence of ductal carcinoma in situ, are known to be 
predictors for local recurrence after BCT. After mastectomy lymph 
node status and tumor size are dominant risk factors for local 
recurrence. Extensive research was therefore aimed at developing and 
validating biomarkers to predict a local recurrence after BCT. 
Recent gene expression profiling studies are already in clinical use for 
predicting prognosis and guiding the indication for adjuvant systemic 
therapy and in some cases also the type of chemotherapy. 
New published and unpublished data reveal that these and other gene 
expression profiles may be used to predict local recurrence after BCT 
or RM. Although the variation in different subtypes in breast cancer 
and the difference in amount of tumor burden remaining after 
surgery, makes that finding robust predictive profiles is still complex.  
During this teaching lecture biomarkers will be presented for 
predicting local recurrence after mastectomy and BCT, and they also 
will be related to the outcome of some recent clinical trials. 
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High dose radiation therapy requires accurate localization of the 
tumor volume and its relationship to surrounding normal tissue. 
Further parameters that influence the results of radiation therapy are 
mainly related to tumor characteristics and the radiation technique 
used. 
As compared to CT, radiotherapy planning with MRI has major 
advantages. Tumor delination by MRI is improved due to its superior 
soft tissue contrast. Furthermore, functional data such as the 
oxygenisation status, pH, and the tissue temperature of the tumor can 
be obtained. In addition MRI does not use ionizing radiation. 
Therefore, MRI maybe optimal for radiotherapy planning. 
However, because of difficulties in image interpretation and image 
distortion as well as missing radiation absorption information it is 
currently not used routinetly. Therefore CT is still used more 
frequently. Thus methods are being developed to convert MRI tissue 
intensities into HU data surrogates for radiation planning. 
Using new fast pulse sequences and standard plastic radiation therapy 
immobilization casts with  MR positive surface markers, MRI may be 
employed more frequently. Areas in which MRI is already used are 
those areas of the body with low or almost no movement such as the 
brain, head and neck-region, and pelvic organs, such as the uterus and 
prostate.  
During the last years positron emission tomography (PET) is of growing 
importance for radiotherapy planning. Since first combined MR-PET-
systems are available MR imaging may play a major role in the future 
of  radiotherapy planning. 
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Intensity-modulated radiotherapy (IMRT) has provided a means for 
shaping the dose distribution not only to the geometry but also to the 
differences in radiobiology across tumors. This information on tumor 
biology and heterogeneity can be derived from functional images. The 
spectrum of imaging biomarkers consists of imaging of tumor 
metabolism (PET with new tracers), angiogenesis (perfusion MRI), 
cellularity (diffusion MRI) and  hypoxia (FMISO PET and BOLD MRI)  
Apart from that, automated segmentation of imaging data, provides 
per pixel measurement of the heterogenous characteristic of the 
tumor in a objective way and improves the assessment of response to 
radiation oncology by imaging.  
This lecture is to learn about the range of MR imaging biomarkers that 
can be used for markers of tumor microenvironment and 
heterogeneity and to understand how these biomarkers can assist 
IMRT in radiotherapy. 
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An important goal in radiotherapy is to minimize the risk of adverse 
side effects following treatment. Geometrical uncertainties make this 
a challenging task because they cause variation in the delivered 
normal tissue dose. A method/concept for handling geometrical 
uncertainties of normal tissue should ideally be able to 1) predict the 
delivered dose to the organ at risk (OAR) in question – within a certain 
probability, 2) allow for correlation of predicted dose-volume 
parameters with adverse effects to develop reliable complication-
/organ-specific constraints, and 3) communicate these constraints to 
the optimization algorithm. 
The ICRU report no.62 introduced the concept of a planning organ at 
risk volume (PRV) to address this problem – in analogy to the planning 
target volume (PTV) [1]. While the PTV should secure the prescribed 
dose to be delivered to the clinical target volume (CTV) with a certain 
probability, the PRV should help controlling normal tissue 
complications. The latter is more challenging both because the shape 
of the dose distribution around OARs is case dependent and will vary 
much more than for the CTV and because the dose-volume response 
varies from organ to organ [2-4]. Consequently, no universal PRV 
recipe – in analogy to the van Herk [5] or Stroom [6] recipes for PTVs – 
exists, and the concept of PRV is somewhat confusing. Inconsistency in 
the ICRU report no. 62 and 83 about for which organ and when to use 
PRVs further contributes to the uncertainty of the concept [1,7]. 
Despite no general PRV recipe – the concept is well established and 
plays an important role in clinical cases where a serial OAR is close to 
a critical dose level (e.g. around the spinal cord in head and neck 
IMRT) [2,3,8,9]. The usefulness of the PRV concept for other 
treatment situations and OARs with a less serial dose-volume response 
is debated [3,10].  
Patient-specific alternatives to PRVs have been suggested and are 
promising [11-16].Some of these concepts completely abandon the use 
of hard margins – both PRVs and PTVs and replace them by directly 
incorporating geometrical uncertainties of the CTVs and OARs in so-
called robust optimization. Implementing these concepts clinically 
would thus require us to reframe our thinking into a more abstract 
way of evaluating dose distributions. Nevertheless, these alternatives 
could help us to better exploit the potentials of advanced 
radiotherapy delivery techniques, including intensity-modulated 
photon and hadron therapy. 
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Historically the standard tool for quality assurance of IMRT has been 
radiographic film, which has had a long history of use in radiotherapy 
QA programs. The trend towards filmless radiology and radiotherapy 
